Clinical Trial Update: A Study of VEGF Tyrosine Kinase Inhibitor (Pazopanib) in Men With High-Risk Prostate Cancer Followed by Radical Prostatectomy and Pelvic Lymph Node Dissection [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating pazopanib (VEGF tyrosine kinase inhibitor) in men with high-risk prostate cancer undergoing radical prostatectomy and pelvic lymph node…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Adenocarcinoma

Drugs mentioned

• Pazopanib (Pazopanib)

Snippet

Sponsor: University of Utah | Conditions: Adenocarcinoma of the Prostate | Phase 2 | Status: COMPLETED | Results posted: 2018-06-12